Search

Your search keyword '"Brunetto, André T."' showing total 31 results
Start Over Author "Brunetto, André T."
31 results on '"Brunetto, André T."'

8. Histone Methyltransferases G9a/Ehmt2 and GLP/Ehmt1 Are Associated with Cell Viability and Poorer Prognosis in Neuroblastoma and Ewing Sarcoma

Author

Souza, Barbara Kunzler, primary, Freire, Natalia Hogetop, additional, Monteiro, Thiago Santos, additional, Herlinger, Alice Laschuk, additional, Jaeger, Mariane, additional, Dalmolin, Matheus G. S., additional, de Farias, Caroline Brunetto, additional, Gregianin, Lauro, additional, Brunetto, André T., additional, Brunetto, Algemir L., additional, Thiele, Carol J., additional, and Roesler, Rafael, additional

Published
2023
Full Text
View/download PDF

10. Histone Methyltransferases G9a/ Ehmt2 and GLP/ Ehmt1 Are Associated with Cell Viability and Poorer Prognosis in Neuroblastoma and Ewing Sarcoma.

Author

Souza, Barbara Kunzler, Freire, Natalia Hogetop, Monteiro, Thiago Santos, Herlinger, Alice Laschuk, Jaeger, Mariane, Dalmolin, Matheus G. S., de Farias, Caroline Brunetto, Gregianin, Lauro, Brunetto, André T., Brunetto, Algemir L., Thiele, Carol J., and Roesler, Rafael

Subjects
HISTONE methyltransferases, EWING'S sarcoma, NEUROBLASTOMA, CELL survival, PROGNOSIS, HISTONES
Abstract

Changes in epigenetic programming have been proposed as being key events in the initiation and progression of childhood cancers. HMT euchromatic histone lysine methyltransferase 2 (G9a, EHMT2), which is encoded by the G9a (Ehmt2) gene, as well as its related protein GLP, which is encoded by the GLP/Ehmt1 gene, participate in epigenetic regulation by contributing to a transcriptionally repressed chromatin state. G9a/GLP activation has been reported in several cancer types. Herein, we evaluated the role of G9a in two solid pediatric tumors: neuroblastoma (NB) and Ewing sarcoma (ES). Our results show that G9a/Ehmt2 and GLP/Ehmt1 expression is higher in tumors with poorer prognosis, including St4 International Neuroblastoma Staging System (INSS) stage, MYCN amplified NB, and metastatic ES. Importantly, higher G9a and GLP levels were associated with shorter patient overall survival (OS) in both NB and ES. Moreover, pharmacological inhibition of G9a/GLP reduced cell viability in NB and ES cells. These findings suggest that G9a and GLP are associated with more aggressive NB and ES tumors and should be further investigated as being epigenetic targets in pediatric solid cancers. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Neurotrophin signaling in medulloblastoma

Author

Thomaz, Amanda, Jaeger, Mariane, Brunetto, Algemir L., Brunetto, André T., Gregianin, Lauro, de Farias, Caroline Brunetto, Ramaswamy, Vijay, Nör, Carolina, Taylor, Michael D., Roesler, Rafael, Thomaz, Amanda, Jaeger, Mariane, Brunetto, Algemir L., Brunetto, André T., Gregianin, Lauro, de Farias, Caroline Brunetto, Ramaswamy, Vijay, Nör, Carolina, Taylor, Michael D., and Roesler, Rafael

Abstract

Neurotrophins are a family of secreted proteins that act by binding to tropomyosin receptor kinase (Trk) or p75NTR receptors to regulate nervous system development and plasticity. Increasing evidence indicates that neurotrophins and their receptors in cancer cells play a role in tumor growth and resistance to treatment. In this review, we summarize evidence indicating that neurotrophin signaling influences medulloblastoma (MB), the most common type of malignant brain cancer afflicting children. We discuss the potential of neurotrophin receptors as new therapeutic targets for the treatment of MB. Overall, activation of TrkA and TrkC types of receptors seem to promote cell death, whereas TrkB might stimulate MB growth, and TrkB inhibition displays antitumor effects. Importantly, we show analyses of the gene expression profile of neurotrophins and their receptors in MB primary tumors, which indicate, among other findings, that higher levels of NTRK1 or NTRK2 are associated with reduced overall survival (OS) of patients with SHH MB tumors.

Published
2020

21. Neurotrophin Signaling in Medulloblastoma

Author

Thomaz, Amanda, primary, Jaeger, Mariane, additional, Brunetto, Algemir L., additional, Brunetto, André T., additional, Gregianin, Lauro, additional, de Farias, Caroline Brunetto, additional, Ramaswamy, Vijay, additional, Nör, Carolina, additional, Taylor, Michael D., additional, and Roesler, Rafael, additional

Published
2020
Full Text
View/download PDF

24. Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma

Author

Thomaz, Amanda, primary, Pinheiro, Kelly de Vargas, additional, Souza, Bárbara Kunzler, additional, Gregianin, Lauro, additional, Brunetto, Algemir L., additional, Brunetto, André T., additional, de Farias, Caroline Brunetto, additional, Jaeger, Mariane da Cunha, additional, Ramaswamy, Vijay, additional, Nör, Carolina, additional, Taylor, Michael D., additional, and Roesler, Rafael, additional

Published
2019
Full Text
View/download PDF

25. HDAC and MAPK/ERK Inhibitors Cooperate to Reduce Viability and Stemness in Medulloblastoma

Author

da Cunha Jaeger, Mariane, primary, Ghisleni, Eduarda Chiesa, additional, Cardoso, Paula Schoproni, additional, Siniglaglia, Marialva, additional, Falcon, Tiago, additional, Brunetto, André T., additional, Brunetto, Algemir L., additional, de Farias, Caroline Brunetto, additional, Taylor, Michael D., additional, Nör, Carolina, additional, Ramaswamy, Vijay, additional, and Roesler, Rafael, additional

Published
2019
Full Text
View/download PDF

26. Targeting histone deacetylase activity to arrest cell growth and promote neural differentiation in Ewing sarcoma

Author

Souza, Bárbara Kunzler, primary, Costa Lopez, Patrícia Luciana da, additional, Menegotto, Pâmela Rossi, additional, Vieira, Igor Araujo, additional, Kersting, Nathalia, additional, Abujamra, Ana Lúcia, additional, Brunetto, André T., additional, Brunetto, Algemir L., additional, Gregianin, Lauro, additional, de Farias, Caroline Brunetto, additional, Thiele, Carol J., additional, and Roesler, Rafael, additional

Published
2017
Full Text
View/download PDF

27. BDNF/TrkB Signaling as a Potential Novel Target in Pediatric Brain Tumors:Anticancer Activity of Selective TrkB Inhibition in Medulloblastoma Cells

Author

Thomaz, Amanda, Jaeger, Mariane, Buendia, Marienela, Bambini-Junior, Victorio, Gregianin, Lauro José, Brunetto, Algemir Lunardi, Brunetto, André T, de Farias, Caroline Brunetto, Roesler, Rafael, Thomaz, Amanda, Jaeger, Mariane, Buendia, Marienela, Bambini-Junior, Victorio, Gregianin, Lauro José, Brunetto, Algemir Lunardi, Brunetto, André T, de Farias, Caroline Brunetto, and Roesler, Rafael

Abstract

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Deregulation of brain-derived neurotrophic factor (BDNF)/tropomyosin-related kinase B (TrkB) signaling has been associated with increased proliferative capabilities, invasiveness, and chemoresistance in several types of cancer. However, the relevance of this pathway in MB remains unknown. Here, we show that the selective TrkB inhibitor N-[2-[[(hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]-benzo[b]thiophene-2-carboxamide (ANA-12) markedly reduced the viability and survival of human cell lines representative of different MB molecular subgroups. These findings provide the first evidence supporting further investigation of TrkB inhibition as a potential novel strategy for MB treatment.

Published
2016

28. BDNF/TrkB Signaling as a Potential Novel Target in Pediatric Brain Tumors: Anticancer Activity of Selective TrkB Inhibition in Medulloblastoma Cells

Author

Thomaz, Amanda, primary, Jaeger, Mariane, additional, Buendia, Marienela, additional, Bambini-Junior, Victorio, additional, Gregianin, Lauro José, additional, Brunetto, Algemir Lunardi, additional, Brunetto, André T., additional, de Farias, Caroline Brunetto, additional, and Roesler, Rafael, additional

Published
2015
Full Text
View/download PDF

30. First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

Author

Brunetto, André T., primary, Ang, Joo Ern, additional, Lal, Rohit, additional, Olmos, David, additional, Molife, L. Rhoda, additional, Kristeleit, Rebecca, additional, Parker, Ann, additional, Casamayor, Isabel, additional, Olaleye, Muyibat, additional, Mais, Anna, additional, Hauns, Bernhard, additional, Strobel, Vera, additional, Hentsch, Bernd, additional, and de Bono, Johann S., additional

Published
2013
Full Text
View/download PDF

31. Cancer Stem Cells and Chemoresistance in Ewing Sarcoma.

Author

Dos Santos RP, Roesler R, Gregianin L, Brunetto AT, da Cunha Jaeger M, Lunardi Brunetto A, and de Farias CB

Subjects
Humans, Drug Resistance, Neoplasm genetics, Cell Line, Tumor, Neoplastic Stem Cells metabolism, Sarcoma, Ewing drug therapy, Sarcoma, Ewing genetics, Sarcoma, Ewing metabolism, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use
Abstract

Resistance to chemotherapy poses a major challenge for cancer treatment. Reactivating a stem cell program resembling that seen in embryonic development can lead cancer cells to acquire a stem-cell phenotype characterized by expression of stemness genes, pluripotency, high self-renewal ability, and tumor-initiating capability. These cancer stem cells (CSCs) are usually resistant to anticancer drugs and are likely involved in treatment failure in many cancer types. Ewing sarcoma (ES) is a pediatric cancer type typically resulting from a typical genetic alteration affecting bone or soft tissues. Despite advances in treatment, survival prognostic remains poor for patients with refractory or recurrent disease. Here, we review the increasing evidence indicating that ES tumors contain a CSC subpopulation expressing stem cell genes, including BM1, OCT3/4, NANOG, and SOX2, that plays a role in resistance to drug treatment, and current experimental strategies that successfully counteract chemoresistance mediated by CSCs in ES., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results